23andMe Genetic Data Bids - Search News

Order byBest matchMost fresh

News

23andMe, Genetic Data

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.

Continue reading

23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction

A drug developer is buying 23andMe - what does that mean for your DNA data?

5h

23andMe to Be Bought by Biotech Company for $256 Million

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Fierce Biotech12h

Regeneron’s $256M bid wins 23andMe bankruptcy auction

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

9hon MSN

23andMe bought by Regeneron in court auction

How exactly 23andMe will shake out after the Regeneron purchase is to be seen. The company has taken a dramatic fall in ...

GEN - Genetic Engineering and Biotechnology News5h

Regeneron to Acquire 23andMe with Winning $256M Bid

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results